追踪接受ALK抑制剂治疗的结直肠癌患者尿液和血液中的CAD-ALK基因重排
本文报告一例携带CAD-ALK易位的转移性结直肠癌患者,在接受ALK抑制剂恩曲替尼治疗期间,利用尿液经肾游离DNA(tr-DNA)和配对血浆循环肿瘤DNA(ctDNA)进行监测。血浆和尿液中CAD-ALK重排的动态变化一致,并与患者临床病程平行;尿液tr-DNA中CAD-ALK融合的检出先于影像学确认疾病进展。血浆ctDNA分析还发现了治疗中出现的ALK激酶突变。作者认为尿液基因检测可无创追踪肿瘤特异性致癌重排,并可用于监测术后微小残留病。
要点
- 血浆和尿液中CAD-ALK重排的动态变化一致,并与患者临床病程平行。
- 尿液tr-DNA中CAD-ALK融合的检出先于影像学确认疾病进展。
- 血浆ctDNA分析发现恩曲替尼治疗期间出现的ALK激酶突变。
核心结论
- 尿液基因检测可追踪肿瘤特异性致癌重排,该策略可有效用于无创监测治疗期间的肿瘤演变。
- 同一方法可用于监测携带基因融合患者根治性手术后的微小残留病,且尿液tr-DNA可自行采集、随时间稳定,并可在指定时间点运送至中心实验室检测,无需患者住院。
研究设计与样本
- 本文为病例报告,研究对象为一例接受ALK抑制剂治疗的携带CAD-ALK易位的转移性结直肠癌患者。
- 利用尿液经肾游离DNA(tr-DNA)和配对血浆循环肿瘤DNA(ctDNA)进行监测。
- 使用定制下一代测序面板鉴定基因组CAD-ALK重排和TP53突变,并开发敏感检测法在尿液tr-DNA中检测这两种改变。
主要发现
- 使用定制下一代测序面板在血浆ctDNA中鉴定出CAD-ALK重排和TP53突变。
- 血浆和尿液中CAD-ALK重排的动态变化一致,并与患者临床病程平行。
- 尿液tr-DNA中CAD-ALK融合的检出先于影像学确认疾病进展。
- 血浆ctDNA分析鉴定出恩曲替尼治疗期间出现的ALK激酶突变。
临床怎么用
- 作者认为尿液基因检测可追踪肿瘤特异性致癌重排,该策略可有效用于无创监测治疗期间的肿瘤演变。
- 作者认为同一方法可用于监测携带基因融合患者根治性手术后的微小残留病。
- 作者指出尿液tr-DNA可自行采集、随时间稳定,并可在指定时间点运送至中心实验室检测,无需患者住院。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Monitoring response and resistance to kinase inhibitors is essential to precision cancer medicine, and is usually investigated by molecular profiling of a tissue biopsy obtained at progression. However, tumor heterogeneity and tissue sampling bias limit the effectiveness of this strategy. In addition, tissue biopsies are not always feasible and are associated with risks due to the invasiveness of the procedure. To overcome these limitations, blood-based liquid biopsy analysis has proven effective to non-invasively follow tumor clonal evolution. PATIENTS AND METHODS: We exploited urine cell-free, trans-renal DNA (tr-DNA) and matched plasma circulating tumor DNA (ctDNA) to monitor a metastatic colorectal cancer patient carrying a CAD-ALK translocation during treatment with an ALK inhibitor. RESULTS: Using a custom next generation sequencing panel we identified the genomic CAD-ALK rearrangement and a TP53 mutation in plasma ctDNA. Sensitive assays were developed to detect both alterations in urine tr-DNA. The dynamics of the CAD-ALK rearrangement in plasma and urine were concordant and paralleled the patient's clinical course. Detection of the CAD-ALK gene fusion in urine tr-DNA anticipated radiological confirmation of disease progression. Analysis of plasma ctDNA identified ALK kinase mutations that emerged during treatment with the ALK inhibitor entrectinib. CONCLUSION: We find that urine-based genetic testing allows tracing of tumor-specific oncogenic rearrangements. This strategy could be effectively applied to non-invasively monitor tumor evolution during therapy. The same approach could be exploited to monitor minimal residual disease after surgery with curative intent in patients whose tumors carry gene fusions. The latter could be implemented without the need of patient hospitalization since urine tr-DNA can be self-collected, is stable over time and can be shipped at specified time-points to central labs for testing.
引用
- Siravegna G, Sartore-Bianchi A, Mussolin B, et al. Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor. Ann Oncol. 2017. PMID: 28368455. doi:10.1093/annonc/mdx095
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。